A phase 1 clinical trial of RES 010 in Non-alcoholic steatohepatitis/Non-alcoholic fatty liver disease
Latest Information Update: 09 Jan 2024
At a glance
- Drugs RES-010 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions
Most Recent Events
- 09 Jan 2024 New trial record